Vimarsana
Biggest News Aggregation in the World

Page 3 - Primary Focus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary Focus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Focus Today - Breaking & Trending Today

Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application - Vimarsana News

Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...

Astellas Submits New Drug Application for Zolbetuximab in Japan - Vimarsana News

Astellas Submits New Drug Application for Zolbetuximab in Japan

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA)...

Gartner Poll Finds 45% of Executives Say ChatGPT Has Prompted an Increase in AI Investment - Vimarsana News

Gartner Poll Finds 45% of Executives Say ChatGPT Has Prompted an Increase in AI Investment

In a recent Gartner, Inc. poll of more than 2,500 executive leaders, 45% reported that the publicity of ChatGPT has prompted them to increase artificial intelligence (AI) investments. Seventy percent of executives said that their organisation is in

Astellas Enters into Definitive Agreement to Acquire Iveric Bio - Vimarsana News

Astellas Enters into Definitive Agreement to Acquire Iveric Bio

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio,...

Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet - Vimarsana News

Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that The Lancet published detailed data from the...